Skip to main content
Premium Trial:

Request an Annual Quote

OpGen Raises $3.5M in Bridge Financing

NEW YORK (GenomeWeb News) – Optical mapping technology firm OpGen has raised $3.5 million in bridge financing.

A company spokesman said the funds raised are bridge financing under a Series C round, but he declined to provide additional details. In a document filed with the US Securities and Exchange Commission on Thursday, the Gaithersburg, Md.-based firm said that it is targeting $3.7 million in the round.

According to the filing, the types of securities offered were debt; options, warrants, or other rights to acquire another security; and security to be acquired upon exercise of option, warrant, or other right to acquire security.

In December, OpGen said in an SEC document that it had raised $2.1 million in bridge financing. That amount is part of the $3.5 million noted in yesterday's SEC filing, company officials said.

The company spokesman said two months ago that the $2.1 million would go toward commercialization of OpGen's flagship technology called the Argus Optical Mapping System, launched in the spring of 2010, which uses optical mapping technology for whole-genome sequence assembly and finishing.

Thursday's SEC document did not identify participants in the financing, but said that 27 people had invested in the offering.

OpGen raised $20 million in a Series B financing round a year ago.

The Scan

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.